Supplementary Fig. S1 from Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer

Elena Shagisultanova; William J. Gradishar; Ursa Brown-Glaberman; Pavani Chalasani; Andrew Brenner; Alison Stopeck; Hannah Parris; Dexiang Gao; Tessa McSpadden; José Mayordomo; Jennifer R. Diamond; Peter Kabos; Virginia F. Borges

doi:10.1158/1078-0432.30833951

Abstract

PK analysis

Related Publications

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Javier Cortés , David W. Cescon , Hope S. Rugo +97 more

Pembrolizumab monotherapy showed durable antitumour activity and manageable safety in patients with metastatic triple-negative breast cancer. We aimed to examine whether the add...

2020 The Lancet 1658 citations

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

Richard S. Finn , Baek‐Yeol Ryoo , Philippe Merle +17 more

PURPOSE Pembrolizumab demonstrated antitumor activity and safety in the phase II KEYNOTE-224 trial in previously treated patients with advanced hepatocellular carcinoma (HCC). K...

2019 Journal of Clinical Oncology 1737 citations

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

William J. Gradishar , Sergei Tjulandin , Neville Davidson +5 more

Purpose ABI-007, the first biologically interactive albumin-bound paclitaxel in a nanameter particle, free of solvents, was compared with polyethylated castor oil–based standard...

2005 Journal of Clinical Oncology 2071 citations

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

Rashmi K. Murthy , Sherene Loi , Alicia Okines +29 more

In heavily pretreated patients with HER2-positive metastatic breast cancer, including those with brain metastases, adding tucatinib to trastuzumab and capecitabine resulted in b...

2019 New England Journal of Medicine 1224 citations

Trastuzumab-Induced Hepatotoxicity: A Case Report

D. Vucicevic , Elizabeth J. Carey , Nina J. Karlin

Background: Trastuzumab is a humanized monoclonal antibody approved for the treatment of breast cancer with HER2 amplification and/or overe...

2013 Breast Care 4416 citations

Publication Info

Year: 2025
Type: article
Citations: 0
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Supplementary Fig. S1 from Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

OpenAlex

Cite This

APA Style

                            
                                    Elena Shagisultanova, 
                                
                                    William J. Gradishar, 
                                
                                    Ursa Brown-Glaberman
                                
                                et al.
                            
                            (2025). 
                            Supplementary Fig. S1 from Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer. 
                            
                            .
                            https://doi.org/10.1158/1078-0432.30833951

Identifiers

DOI: 10.1158/1078-0432.30833951